clinical trial · NCT07426757
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
Pfizer·phase1·not yet recruiting·n = 120
Advanced MalignanciesAdvanced CancerPF-07994525Midazolam
brief summary
This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.
started
Mar 26, 2026
primary completion
Jul 8, 2029
completion
Jul 8, 2030
last updated
Apr 7, 2026
official title
An Open-Label Phase 1 Study to Evaluate PF-07994525 in Participants With Advanced Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol